LC
INSM icon

Lindbrook Capital’s Insmed INSM Stock Holding History

Lindbrook Capital’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$30.7K Buy
402
+44
+12% +$3.37K ﹤0.01% 1176
2024
Q4 		$24.7K Sell
358
-17
-5% -$1.22K ﹤0.01% 1157
2024
Q3 		$27.4K Sell
375
-143
-28% -$10.6K ﹤0.01% 1120
2024
Q2 		$34.7K Buy
518
+91
+21% +$3.53K ﹤0.01% 960
2024
Q1 		$11.6K Hold
427
– – ﹤0.01% 1492
2023
Q4 		$13.2K Sell
427
-111
-21% -$2.88K ﹤0.01% 1393
2023
Q3 		$13.6K Buy
538
+61
+13% +$1.4K ﹤0.01% 1256
2023
Q2 		$10.1K Buy
477
+160
+50% +$3.04K ﹤0.01% 1463
2023
Q1 		$5.41K Sell
317
-201
-39% -$3.9K ﹤0.01% 1822
2022
Q4 		$10.3K Sell
518
-227
-30% -$4.39K ﹤0.01% 1418
2022
Q3 		$16K Buy
745
+55
+8% +$1.32K ﹤0.01% 1101
2022
Q2 		$14K Sell
690
-5
-0.7% -$105 ﹤0.01% 1126
2022
Q1 		$16K Sell
695
-1,479
-68% -$34.4K ﹤0.01% 1103
2021
Q4 		$59K Buy
+2,174
New +$62.2K 0.01% 663

Other funds holding INSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Lindbrook Capital's INSM Position: Q1 2025 in Review

Lindbrook Capital increased its Insmed (INSM) stake by 12% in Q1 2025, buying an estimated $3.37K and bringing the position to 402 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Lindbrook Capital first reported a position in INSM in Q4 2021 and has held it in 14 quarters since. The position peaked at $59K in Q4 2021. 441 funds tracked by Wall St. Rank hold INSM as of Q1 2025.

  • Lindbrook Capital held 402 shares of Insmed worth $30.7K as of Q1 2025.
  • Lindbrook Capital bought 44 Insmed shares in Q1 2025, an estimated $3.37K.
  • Insmed made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1176 holding.
  • Lindbrook Capital first reported a position in Insmed in Q4 2021 and has held it in 14 quarters since.
  • Lindbrook Capital's Insmed position peaked at $59K in Q4 2021.
  • 441 funds tracked by Wall St. Rank held Insmed as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.